Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23054219 | 0.87 | MEN1 (0.45) | TP53SMN1; SMN2HDAC1HDAC6MEN1 | |
| SCHEMBL21792306 | 0.84 | SRD5A1 (0.52) | TP53SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL20173808 | 0.82 | RARA (0.47) | TP53SMN1; SMN2POLBHDAC1HDAC6 | |
| SCHEMBL12043752 | 0.81 | MAPT (0.50) | TP53SMN1; SMN2POLBHDAC1HDAC6 | |
| SCHEMBL12043753 | 0.80 | TP53 (0.49) | TP53SMN1; SMN2POLBHDAC1HDAC6 | |
| SCHEMBL20173807 | 0.78 | SRD5A1 (0.56) | TP53SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL20173810 | 0.78 | ALDH1A1 (0.51) | TP53SMN1; SMN2POLBHDAC1HDAC6 | |
| SCHEMBL7670996 | 0.77 | HDAC1 (0.49) | TP53SMN1; SMN2HDAC1HDAC6MEN1 | |
| SCHEMBL25873240 | 0.77 | POLB (0.50) | TP53POLBHDAC1HDAC6MEN1 | |
| SCHEMBL25857610 | 0.75 | PRKCI (0.43) | TP53SMN1; SMN2HDAC1HDAC6MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227826-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | ARCTURUS THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227826-A1 | UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES | HNRNPR, HNRNPK, ATXN2 | TP53 3616/4885SMN1; SMN2 280/4885POLB 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.